Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
3
50%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (33.3%)
Phase 33 (50.0%)
Phase 41 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853
completedphase_2

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

NCT01125514
completedphase_3

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

NCT00777946
completedphase_3

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

NCT00706134
completedphase_3

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension

NCT00705575
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03115853Phase 4

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Completed
NCT01125514Phase 2

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

Completed
NCT00777946Phase 3

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Completed
NCT00706134Phase 3

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Completed
NCT00705575Phase 3

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension

Completed
NCT00409578Phase 2

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6